Attention Deficit Disorder With Hyperactivity (ADHD) Completed Phase 1 Trials for Bavisant (DB12299)

Also known as: Attention Deficit Hyperactivity Disorder / Attention Deficit Hyperactivity Disorder (ADHD) / Attention Deficit Hyperactivity Disorders / Attention Deficit/Hyperactivity Disorder (ADHD) / Attention Deficit/Hyperactivity Disorder(ADHD) / Attention-Deficit/Hyperactivity Disorder (ADHD) / Attention-Deficit Hyperactivity Disorder (ADHD) / Attention-Deficit Hyperactivity Disorder / ADHD / [X]Hyperkinetic disorder, unspecified (disorder) / ADDH / Attention deficit hyperactivity disorder, predominantly hyperactive impulsive type (disorder) / Hyperactive child syndrome / Attention deficit disorder / Attention deficit disorder of childhood with hyperactivity / ADHD, predominantly hyperactive-impulsive type / Attention deficit/hyperactivity disorder NOS / Attention deficit/hyperactivity disorder / Attention deficit-hyperactivity disorder / Attention-deficit hyperactivity disorders / Attention Deficit Disorder with Hyperactivity / Attention deficit hyperactivity disorder (disorder) / Unspecified hyperkinetic syndrome of childhood / Childhood hyperkinetic syndrome / Hyperkinetic syndrome of childhood / Hyperkinetic syndrome NOS (disorder) / Hyperkinetic syndrome / Syndrome hyperkinetic

IndicationStatusPhase
DBCOND0036220 (Attention Deficit Disorder With Hyperactivity (ADHD))Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00890292A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)Basic Science
NCT00890240A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)Basic Science